Melissa Johnson, MD
Associate Director, Lung Cancer Research and Drug Development
Dr. Johnson joined Sarah Cannon in 2014 and serves as the associate director of lung cancer research and drug development. Her responsibilities include supporting the growth of the phase 2/3 Lung Program clinical trial portfolio, while also furthering the development of early phase compounds for thoracic malignancies in the drug development unit.
Dr. Johnson received her undergraduate degree from the University of North Carolina, Chapel Hill and her medical degree from the University of Pennsylvania. She completed her residency in internal medicine at New York Presbyterian/Weill Cornell Medical Center and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center where she also served as chief fellow for one year. She spent four years as a faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Feinberg School of Medicine, where she was a founding member of the Northwestern Medical Developmental Therapeutics Institute (NMDTI). She is board certified in internal medicine and medical oncology. Additionally, she is a partner of Tennessee Oncology, PLLC.